In the past week, ADAP stock has gone up by 3.26%, with a monthly decline of -13.40% and a quarterly plunge of -18.00%. The volatility ratio for the week is 7.28%, and the volatility levels for the last 30 days are 7.32% for Adaptimmune Therapeutics Plc ADR The simple moving average for the last 20 days is -2.08% for ADAP stock, with a simple moving average of -52.73% for the last 200 days.
Is It Worth Investing in Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Right Now?
The stock has a 36-month beta value of 2.23. Opinions on the stock are mixed, with 3 analysts rating it as a “buy”, 2 as “overweight”, 4 as “hold”, and 0 as “sell”.
The public float for ADAP is 228.63M, and at present, short sellers hold a 2.00% of that float. On July 03, 2025, the average trading volume of ADAP was 1.13M shares.
ADAP stock’s latest price update
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP)’s stock price has plunge by 3.18%relation to previous closing price of $0.24. Nevertheless, the company has seen a 3.26% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-13 that Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Juli Miller – Investor Relations Adrian Rawcliffe – Chief Executive Officer Cintia Piccina – Chief Commercial Officer Dennis Williams – SVP, Late Stage Development Gavin Wood – CFO John Lunger – VP, Manufacturing Conference Call Participants Marc Frahm – TD Cowen Jonathan Chang – SVB Leerink Arthur He – H.C. Wainwright Graig Suvannavejh – Mizuho Yanan Zhu – Wells Fargo Securities Operator Hello and welcome to Adaptimmune’s First Quarter 2025 Business Update Conference Call.
Analysts’ Opinion of ADAP
Many brokerage firms have already submitted their reports for ADAP stocks, with Mizuho repeating the rating for ADAP by listing it as a “Neutral”. The predicted price for ADAP in the upcoming period, according to Mizuho is $0.50 based on the research report published on June 26, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ADAP reach a price target of $4. The rating they have provided for ADAP stocks is “Buy” according to the report published on July 30th, 2024.
Bryan Garnier gave a rating of “Buy” to ADAP, setting the target price at $3.60 in the report published on March 24th of the previous year.
ADAP Trading at -7.49% from the 50-Day Moving Average
After a stumble in the market that brought ADAP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.10% of loss for the given period.
Volatility was left at 7.32%, however, over the last 30 days, the volatility rate increased by 7.28%, as shares sank -11.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.32% lower at present.
During the last 5 trading sessions, ADAP rose by +4.71%, which changed the moving average for the period of 200-days by -77.15% in comparison to the 20-day moving average, which settled at $0.2557. In addition, Adaptimmune Therapeutics Plc ADR saw -76.18% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADAP starting from Norry Elliot, who sold 5,584 shares at the price of $0.58 back on Jan 17 ’25. After this action, Norry Elliot now owns 7,510 shares of Adaptimmune Therapeutics Plc ADR, valued at $3,243 using the latest closing price.
Lunger John, the Chief Patient Supply Officer of Adaptimmune Therapeutics Plc ADR, sale 5,584 shares at $0.58 during a trade that took place back on Jan 17 ’25, which means that Lunger John is holding 7,510 shares at $3,243 based on the most recent closing price.
Stock Fundamentals for ADAP
Current profitability levels for the company are sitting at:
- -0.36% for the present operating margin
- 0.98% for the gross margin
The net margin for Adaptimmune Therapeutics Plc ADR stands at -0.39%. The total capital return value is set at -0.61%. Equity return is now at value -273.36%, with -33.40% for asset returns.
Based on Adaptimmune Therapeutics Plc ADR (ADAP), the company’s capital structure generated -1.65 points at debt to capital in total, while cash flow to debt ratio is standing at -4.63. The debt to equity ratio resting at -0.62. The interest coverage ratio of the stock is -12.48.
Currently, EBITDA for the company is -52.66 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of 0.26. The receivables turnover for the company is 40.99for trailing twelve months and the total asset turnover is 1.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.02.
Conclusion
To sum up, Adaptimmune Therapeutics Plc ADR (ADAP) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
